Immune Checkpoint Blockade in Lung Cancer

被引：0
|
作者：
Somasundaram, Aswin [1 ]
Socinski, Mark A. [1 ]
Villaruz, Liza C. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA 15232 USA
来源：
DISCOVERY MEDICINE | 2016年 / 22卷 / 119期
关键词：
UP-REGULATION; DOUBLE-BLIND; MULTICENTER; EXPRESSION; NIVOLUMAB; SAFETY; LYMPHOCYTES; DOCETAXEL; ANTIBODY; PHASE-2;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the therapeutic landscape of advanced lung cancer. The adaptive immune system has developed a sophisticated method of tumor growth control, but T-cell activation is regulated by various checkpoints. Blockade of the immune checkpoints with therapies targeting the PD-1 pathway, such as nivolumab and pembrolizumab, has been validated as a therapeutic approach in non-small cell lung cancer. Newer therapies and novel combinations are also being evaluated, and the use of biomarkers in conjunction with these drugs is an area of active investigation. This review summarizes the current evidence for the efficacy and safety of the above approaches in the treatment of lung cancer.
引用
收藏
页码：56 / 66
页数：11
相关论文
共 50 条
  • [31] The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer
    Liu, Xiangzheng
    Shang, Xueqian
    Li, Jian
    Zhang, Shijie
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [32] Immune-Related Adverse Events Associated with Immune Checkpoint Blockade in Lung Cancer - A restrospective study
    Braco Forte, Cristina Isabel
    Almodovar, Teresa
    Duarte, Isabel
    Da Costa, Jose Duro
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [33] Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer
    Tang, Bufu
    Wang, Yajie
    Xu, Wangting
    Zhu, Jinyu
    Weng, Qiaoyou
    Chen, Weiqian
    Fang, Shiji
    Yang, Yang
    Qiu, Rongfang
    Chen, Minjiang
    Mao, Weiyang
    Xu, Min
    Zhao, Zhongwei
    Cai, Songhua
    Zhang, Hongbing
    Ji, Jiansong
    CANCER LETTERS, 2023, 554
  • [34] Role of the THE in immune checkpoint blockade resistance of non-small cell lung cancer
    Dai, Yuening
    Tian, Xueqi
    Ye, Xuanting
    Gong, Yabin
    Xu, Ling
    Jiao, Lijing
    CANCER DRUG RESISTANCE, 2024, 7
  • [35] Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer
    Saxena, Ashish
    SEMINARS IN CANCER BIOLOGY, 2023, 90 : 45 - 56
  • [36] Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
    Califano, Raffaele
    Kerr, Keith
    Morgan, Robert David
    Lo Russo, Giuseppe
    Garassino, Marina
    Morgillo, Floriana
    Rossi, Antonio
    CURRENT ONCOLOGY REPORTS, 2016, 18 (09)
  • [37] Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
    Moeller, Miriam
    Turzer, Steffi
    Schuette, Wolfgang
    Seliger, Barbara
    Riemann, Dagmar
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (02) : 57 - 66
  • [38] Prognostic Signature of Response to PD-1 Immune Checkpoint Blockade in Lung Cancer
    Ding, Juan
    Sun, Tingting
    Yao, Juan
    Zheng, Ni
    Lu, Rong
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2023, 37 (02): : 617 - 628
  • [39] Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
    Raffaele Califano
    Keith Kerr
    Robert David Morgan
    Giuseppe Lo Russo
    Marina Garassino
    Floriana Morgillo
    Antonio Rossi
    Current Oncology Reports, 2016, 18
  • [40] Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
    Riess, Jonathan W.
    Lara, Primo N., Jr.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3717 - +
12345